Skip to main content
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2015 Dec 9;29(12):2452. doi: 10.1038/leu.2015.312

Erratum: Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

A F List, J M Bennett, M A Sekeres, B Skikne, T Fu, J M Shammo, S D Nimer, R D Knight, A Giagounidis; on behalf of the MDS-003 Study Investigators
PMCID: PMC7608406  PMID: 26648407

Correction to: Leukemia (2014) 28, 1033–1040; doi:10.1038/leu.2013.305

Since the publication of this article it has been noted that there was an omission in the listing of conflict of interest. JM Bennett was listed as having no conflict of interest; however, the authors would like to correct this to read:

‘JMB is a consultant for and has received honoraria and contract monies as a consulting hematomorphologist from the Celgene Corporation’.

The authors apologise for any inconvenience caused by this error.

Footnotes

The online version of the original article can be found at 10.1038/leu.2013.305


Articles from Leukemia are provided here courtesy of Nature Publishing Group

RESOURCES